• MDB Capital unit PatentVest published a Pulse report mapping a muscle-preservation drug category aimed at improving long-term GLP-1 obesity outcomes.
• Analysis identified 20 muscle-preservation programs in development, signaling rising investment in lean-mass retention during pharmacological weight loss.
• Report flagged myostatin inhibition, ActRII blockade, and GLP-1 combination strategies as key approaches shaping next-stage obesity therapeutics.
• Industry deal activity cited as validation, including Eli Lilly’s Versanis Bio acquisition for bimagrumab, AstraZeneca’s SixPeaks Bio acquisition.
• Patent strategy focus highlighted around combination-therapy claims, method-of-use protections, and pathway-specific IP as competitive positioning tightens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDB Capital Holdings LLC published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041305PRIMZONEFULLFEED9732065) on June 04, 2026, and is solely responsible for the information contained therein.